Lung Cancer Clinical Trial
Official title:
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Verified date | May 2018 |
Source | Butler Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is
not yet known whether varenicline is more effective than the nicotine patch given together
with nicotine gum in helping smokers quit smoking.
PURPOSE: This randomized clinical trial is studying varenicline to see how well it works
compared with the nicotine patch given together with nicotine gum in helping smokers in a
methadone treatment program stop smoking.
Status | Completed |
Enrollment | 315 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
INCLUSION CRITERIA - Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months) - Interested in quitting smoking - Willing to set a quit date 7 days after baseline assessment - Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island at any of the following institutions: - Codac, Inc. (with two independent sites) - Addiction Recovery Institute - Center for Treatment and Recovery - Discovery House - Has received methadone for at least the past month EXCLUSION CRITERIA - Pregnant or nursing (Must have negative pregnancy test) - Non-English speaking - No personal telephone or does not live close to a relative or neighbor with a telephone - Unwilling to make their methadone dose and methadone maintenance treatment program urine toxicologies available for review - Unvailable for this study for the next 12 months - Suffering from any unstable medical condition which would preclude the use of the nicotine patch (e.g., unstable angina or uncontrolled hypertension) - Active skin condition (e.g., psoriasis) - History of skin allergy - History of a suicide attempt - Working as pilots, drivers, or operators of heavy machinery PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No concurrent insulin or blood thinners - No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking cessation treatment |
Country | Name | City | State |
---|---|---|---|
United States | Rhode Island Hospital Comprehensive Cancer Center | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Butler Hospital | National Cancer Institute (NCI) |
United States,
Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013 Dec 1;133(2):486-93. doi: 10.1016/j.drugalcdep.2013.07.005. Epub 2013 Aug 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Self- Reported 7-day Abstinence | Number of participants with self-reported, 7-day abstinence at 6-months | 6 Months | |
Primary | Carbon Monoxide (CO)-Confirmed 7-day Abstinence | Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement. | 6-Months | |
Primary | Rates of Smoking Cessation Continuous From First Quit Day to 6 Months | Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months | 6-Months | |
Primary | Self-reported 7-day Abstinence | Number of participants with self-reported 7-day abstinence at 12-months | 12 Months | |
Primary | CO-confirmed 7-day Abstinence | Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement. | 12 Months | |
Secondary | Change in Smoking Urges | Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale. Higher values represent greater urge to smoke. Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score. | 6 months | |
Secondary | Withdrawal Symptoms | Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale. The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe). Higher values indicate more severe withdrawal symptoms. Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score. | 6 months | |
Secondary | Retention in Methadone Maintenance | 12 months | ||
Secondary | Methadone Dose Changes | 12 months | ||
Secondary | Use of Illicit Drugs as Measured by Urine Toxicologies | 12 months | ||
Secondary | Reinforcing Effects of Smoking | Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire. Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely). Higher values indicated that smoking was a more positive experience for 10 of 12 items. Two items were reverse coded. Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score. | 6 months | |
Secondary | Change in Cigarettes Per Day | Change in mean cigarettes per day | 6-Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|